[1] MOREB JS, BYRNE M, ZOU F, et al.Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation [J].J Clin Apher, 2018, 33 (1):29. doi: 10.1002/jca.21556
[2] SHAH H, KIM S, SINGH P, et al.Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts [J].Am J Hematol, 2020, 95(2):198. doi: 10.1002/ajh.25672
[3] FIGUEIREDO A, KASSIS R, ALBACKER R, et al.The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection:25-year experience [J].Hematol Transfus Cell Ther, 2019, 41 (4):285. doi: 10.1016/j.htct.2019.03.005
[4] GIRALT S, COSTA L, SCHRIBER J, et al.Optimizing autologous stem cell mobilization strategies to improve patient outcomes:consensus guidelines and recommendations[J].Biol Blood Marrow Transplant, 2014, 20(3):295. doi: 10.1016/j.bbmt.2013.10.013
[5] KIM SS, RENTERIA AS, STEINBRERG A, et al.Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma[J].Cytotherapy, 2014, 16(11):1584. doi: 10.1016/j.jcyt.2014.05.003
[6] GIRALT S, COSTA L, SCHRIBER J, et al.Optimizing autologous stem cell mobilization strategies to improve patient outcomes:consensus guidelines and recommendations[J].Biol Blood Marrow Transplant, 2014, 20(3):295. doi: 10.1016/j.bbmt.2013.10.013
[7] SAHIN U, DEMIRER T.Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma[J].J Clin Apher, 2018, 33(3):357. doi: 10.1002/jca.21591
[8] ABDALLAH N, KIM S, AYASH L, et al.Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant?[J].Bone Marrow Transplant, 2020, 55(8):1655. doi: 10.1038/s41409-019-0744-5
[9] GOKER H, CIFTCILER R, DEMIROGLU H, et al.Predictive factors for stem cell mobilization failure in multiple myeloma patients:a single center experience[J].Transfus Apher Sci, 2020, 59(1):102595. doi: 10.1016/j.transci.2019.06.023
[10] LAGRESLE PEYROU C, LEFRERE F, MAGRIN E, et al.Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion[J].Haematologica, 2018, 103(5):778. doi: 10.3324/haematol.2017.184788
[11] SHAH EE, YOUNG RP, WONG SW, et al.Impact of plerixafor use at different peripheral blood CD34 thresholds on autologous stem cell collection in patients with multiple myeloma[J].Biol Blood Marrow Transplant, 2020, 26(5):876. doi: 10.1016/j.bbmt.2019.11.024
[12] GUTIERRES AGUIRRE CH, ALVARADO-NAVARRO DM, PALOMARES LEAL A, et al.Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation:a proof of concept study[J].Transfusion, 2019, 59(12):3721. doi: 10.1111/trf.15547
[13] KUMAR SK, BERDEJA JG, NIESVIZKY R, et al.Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma:an open-label phase 1/2 study[J].Lancet Oncol, 2014, 15(13):1503. doi: 10.1016/S1470-2045(14)71125-8
[14] BUNEO JL, ALEGRE A, LOPEA VILLAR O, et al.Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection.A Spanish consensus document[J].Bone Marrow Transplant, 2020, 55(4):811. doi: 10.1038/s41409-019-0716-9